Jane Street Group LLC increased its stake in shares of MiMedx Group, Inc. (NASDAQ:MDXG - Free Report) by 133.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 305,652 shares of the company's stock after purchasing an additional 174,797 shares during the quarter. Jane Street Group LLC owned approximately 0.21% of MiMedx Group worth $1,806,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also modified their holdings of MDXG. Victory Capital Management Inc. raised its stake in MiMedx Group by 909.0% during the second quarter. Victory Capital Management Inc. now owns 138,449 shares of the company's stock worth $959,000 after acquiring an additional 124,727 shares in the last quarter. Farther Finance Advisors LLC lifted its holdings in shares of MiMedx Group by 88.6% during the 3rd quarter. Farther Finance Advisors LLC now owns 24,599 shares of the company's stock valued at $145,000 after purchasing an additional 11,557 shares in the last quarter. Isthmus Partners LLC raised its holdings in shares of MiMedx Group by 30.4% during the second quarter. Isthmus Partners LLC now owns 393,214 shares of the company's stock worth $27,000 after acquiring an additional 91,714 shares during the period. Harbor Capital Advisors Inc. boosted its position in shares of MiMedx Group by 299.9% during the third quarter. Harbor Capital Advisors Inc. now owns 1,027,738 shares of the company's stock worth $6,074,000 after buying an additional 770,744 shares during the period. Finally, Dimensional Fund Advisors LP raised its holdings in shares of MiMedx Group by 47.0% in the second quarter. Dimensional Fund Advisors LP now owns 1,292,822 shares of the company's stock valued at $8,958,000 after purchasing an additional 413,443 shares during the last quarter. 79.15% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
Separately, StockNews.com cut MiMedx Group from a "strong-buy" rating to a "buy" rating in a research note on Friday, November 8th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $12.00.
Check Out Our Latest Stock Report on MiMedx Group
MiMedx Group Price Performance
NASDAQ MDXG traded up $0.26 during trading on Thursday, reaching $9.39. The company's stock had a trading volume of 355,757 shares, compared to its average volume of 749,346. The firm has a fifty day moving average of $8.21 and a 200 day moving average of $7.13. MiMedx Group, Inc. has a one year low of $5.47 and a one year high of $10.14. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.10 and a quick ratio of 3.53. The stock has a market capitalization of $1.38 billion, a PE ratio of 17.07 and a beta of 1.97.
MiMedx Group Profile
(
Free Report)
MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.
Further Reading
Before you consider MiMedx Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MiMedx Group wasn't on the list.
While MiMedx Group currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
